I-Mab and Jiangsu Nhwa collaborate with Biodextris and Ann Romney CND
Category: #health  By Mateen Dalal  Date: 2019-04-08
  • share
  • Twitter
  • Facebook
  • LinkedIn

I-Mab and Jiangsu Nhwa collaborate with Biodextris and Ann Romney CND

The strategic partnership is aimed at jointly developing a new immuno-stimulatory therapy for certain neurologic disorders.

I-Mab Biopharma, a Shanghai-based biotech company, along with the CNS (Central Nervous System) drug development company Jiangsu Nhwa Pharmaceutical, has signed a collaborative research agreement with the world-recognized scientists and clinicians at Biodextris, the biologics contract development & manufacturing organization, and Ann Romney CND (Center for Neurologic Diseases) at Brigham and Women’s Hospital.

Reportedly, the strategic partnership is aimed at jointly developing a new immuno-stimulatory therapy for certain neurologic disorders, with the deployment of the natural power of the immune system. As per the terms of the agreement, the parties are expected to combine their expertise and resources in translational research, basic science, clinical development, manufacturing & commercialization, for speeding up the translation of innovative immunotherapies into the clinic, for some of the most challenging diseases with the greatest unmatched medical needs.

According to a press release issued by I-Mab Biopharma, the Brigham team will be accountable for the preclinical development such as biomarker discovery & validation, and preliminary clinical studies. Biodextris on the other hand, will contribute to CMC development & manufacturing of clinical materials. Sources added that I-Mab and Nhwa will be providing all technical, financial, regulatory and business support for both preclinical and clinical development, along with future commercialization.  

Dr. Zheru Zhang, President, I-Mab, was reportedly quoted saying that the Brigham is globally recognized for its innovation and brilliance in the area of patient care and biomedical research. The latest international collaboration between the industry and a top academic institute is believed to accelerate drug development and scientific advancement as well. He added that I-Mab shares the same goal and has been consistently striving to provide patients around the world with innovative treatments.

Howard L Weiner, Co-director at the Ann Romney Center, said that the advancement of a nasal immune modulator used in vaccines is an exceptional approach towards the treatment of a neurologic disease and moreover, is potent enough to majorly impact the disease prevalence on a global level.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Ather Energy raises $250 million to stay ahead in competition
Ather Energy raises $250 million to stay ahead in competition
By Mateen Dalal

Electric scooter producer Ather Energy has reportedly secured $250 million in a new funding round. As per reports, the investment round is in its early stages. The company’s goal is to obtain $200 million to $250 million to compete in the EV...

Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
By Mateen Dalal

Mojocare, a wellness and health startup has reportedly raised USD 20.6 million in a Series A round of funding which was led by B Capital Group and saw participation from existing investors including Sequoia India’s Surge, Better Capital, and Ch...

Exponent Energy bags USD 13 million in Lightspeed-led Series A funding
Exponent Energy bags USD 13 million in Lightspeed-led Series A funding
By Mateen Dalal

Bangalore-based Exponent Energy has reportedly secured USD 13 million in a Series A funding round which was spearheaded by Lightspeed Venture Partners. The round also saw participation from existing investors such as 3one4 Capital, YourNest VC, and A...